Morgan Stanley Issues Pessimistic Forecast for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN) had its price target reduced by equities research analysts at Morgan Stanley from $16.00 to $15.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 31.26% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Organon & Co. has an average rating of “Hold” and an average price target of $20.60.

Organon & Co. Trading Down 9.6 %

Shares of NYSE OGN opened at $11.43 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a one year low of $11.05 and a one year high of $23.10. The business has a 50-day moving average price of $14.71 and a two-hundred day moving average price of $15.72. The firm has a market capitalization of $2.95 billion, a PE ratio of 3.43, a PEG ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. As a group, analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Organon & Co.

Several institutional investors have recently bought and sold shares of OGN. Horizon Bancorp Inc. IN boosted its stake in shares of Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. Millstone Evans Group LLC bought a new stake in Organon & Co. during the fourth quarter worth approximately $29,000. Larson Financial Group LLC grew its holdings in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after purchasing an additional 1,734 shares during the last quarter. Riverview Trust Co raised its position in shares of Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after buying an additional 1,324 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.